BIOMAT Database Logo BIOMAT Database Logo

Zidovudine with probenecid: a warning. 1990

B G Petty, and D M Kornhauser, and P S Lietman

UI MeSH Term Description Entries
D008297 Male Males
D011339 Probenecid The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. Benecid,Benemid,Benuryl,Pro-Cid,Probecid,Probenecid Weimer
D011358 Product Surveillance, Postmarketing Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale. Drug Surveillance, Postmarketing,Evaluation Studies, Postmarketing,Postmarketing Product Surveillance,Product Surveillance, Post-Marketing,Drug Surveillances, Postmarketing,Evaluation Study, Postmarketing,Post-Marketing Product Surveillance,Post-Marketing Product Surveillances,Postmarketing Drug Surveillance,Postmarketing Drug Surveillances,Postmarketing Evaluation Studies,Postmarketing Evaluation Study,Postmarketing Product Surveillances,Product Surveillance, Post Marketing,Product Surveillances, Post-Marketing,Product Surveillances, Postmarketing,Studies, Postmarketing Evaluation,Study, Postmarketing Evaluation,Surveillance, Post-Marketing Product,Surveillance, Postmarketing Drug,Surveillance, Postmarketing Product,Surveillances, Post-Marketing Product,Surveillances, Postmarketing Drug,Surveillances, Postmarketing Product
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

B G Petty, and D M Kornhauser, and P S Lietman
Zidovudine with probenecid.
August 1990, Lancet (London, England),
B G Petty, and D M Kornhauser, and P S Lietman
Pharmacokinetics of zidovudine plus probenecid.
September 1992, The Journal of infectious diseases,
B G Petty, and D M Kornhauser, and P S Lietman
Pharmacokinetic evaluation of drug interactions with zidovudine. I: Probenecid and zidovudine in monkeys.
November 1991, Journal of pharmaceutical sciences,
B G Petty, and D M Kornhauser, and P S Lietman
Interaction of zidovudine (azidothymidine) with isoprinosine and probenecid in Macaca fascicularis.
January 1994, Pharmaceutical research,
B G Petty, and D M Kornhauser, and P S Lietman
Competitive inhibition of zidovudine clearance by probenecid during continuous coadministration.
February 1992, Pharmaceutical research,
B G Petty, and D M Kornhauser, and P S Lietman
Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex.
November 1989, Clinical pharmacology and therapeutics,
B G Petty, and D M Kornhauser, and P S Lietman
A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats.
December 1991, The Journal of pharmacology and experimental therapeutics,
B G Petty, and D M Kornhauser, and P S Lietman
Probenecid inhibits the metabolic and renal clearances of zidovudine (AZT) in human volunteers.
April 1990, Pharmaceutical research,
B G Petty, and D M Kornhauser, and P S Lietman
Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
March 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
B G Petty, and D M Kornhauser, and P S Lietman
Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid.
December 1997, Journal of pharmaceutical sciences,
Copied contents to your clipboard!